Esperion Therapeutics Profit Margin

The latest profit margin for ESPR is 0.12% as of March 2026. That compares with -59.03% in the prior-year period — up 100.2% year over year. That is below the Healthcare sector average of 9.71%. Investors often review this figure alongside Esperion Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ESPR's profit margin moved from -59.03% to 0.12% — a 100.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Esperion Therapeutics's valuation or profitability profile.

Against Healthcare companies, ESPR currently prints 0.12% for profit margin, while the sector average sits near 9.71%. That is roughly 98.7% below the sector mean. Large gaps often invite a closer look at Esperion Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Esperion Therapeutics converts resources into returns. At 0.12%, ESPR may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -59.03% in the prior-year period — up 100.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ESPR's profit margin (0.12%), review year-over-year change from -59.03%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.